Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
|Videos|September 10, 2015
Biosimilars Poised to Impact Specialty Pharmacy
Author(s)Davy James, Managing Editor
Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses the projected ramifications from the launch of biosimilars in the United States.
Advertisement
Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses the projected ramifications from the launch of biosimilars in the United States.
This video was recorded courtesy of Armada Health Care at the 2015 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.
Advertisement
Related to this article
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What the 2025-2030 Dietary Guidelines Mean for Heart Health
2
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
3
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
4
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
5